Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

Abstract Background Although epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have been the standard treatment for advanced EGFR‐mutant adenocarcinoma, the effects of upfront EGFR‐TKI use in unresectable stage III EGFR‐mutant adenocarcinoma remain unexplored. Here, we conducte...

Full description

Bibliographic Details
Main Authors:	Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Thoracic Cancer
Subjects:	adenocarcinoma chemoradiotherapy epidermal growth factor receptor stage III tyrosine kinase inhibitors
Online Access:	https://doi.org/10.1111/1759-7714.14237

Similar Items

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
by: Chia-Yu Kuo, et al.
Published: (2022-12-01)

Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
by: Chung‐Fu Lin, et al.
Published: (2022-02-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
by: Ping-Chih Hsu, et al.
Published: (2023-10-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
by: Seo Yun Kim, M.D., et al.
Published: (2019-01-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
by: Xiaosheng Ding, et al.
Published: (2023-10-01)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
by: Tai-Huang Lee, et al.
Published: (2022-06-01)

Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review
by: Yun-Zhu Xi, et al.
Published: (2022-09-01)

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
by: Cheng-Yu Chang, et al.
Published: (2023-06-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients
by: Xiao-Jing Du, et al.
Published: (2018-12-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
by: Min Yu, et al.
Published: (2022-06-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
by: Carlo Buonerba, et al.
Published: (2019-08-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
by: Ying-Yi Chen, et al.
Published: (2023-10-01)

Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer：a Meta-analysis
by: LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe
Published: (2022-03-01)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
by: Marc-Eric Halatsch, et al.
Published: (2012-05-01)

4-Aryl-N-phenylpyrimidin-2-amines targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines
by: Lueacha Tabtimmai, et al.
Published: (2022-08-01)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with <i>EGFR</i>-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
by: Ming-Ju Tsai, et al.
Published: (2023-03-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
by: Wei‐Chun Chen, et al.
Published: (2024-04-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)